Metformin Use Is Associated with Decreased Mortality in COVID-19 Patients with Diabetes: Evidence from Retrospective Studies and Biological Mechanism
Tahmina Nasrin Poly, Md. Mohaimenul Islam, Yu-Chuan (jack) Li, Ming-Chin Lin, Min-Huei Hsu, Yao-Chin Wang
Journal of Clinical Medicine, doi:10.3390/jcm10163507
Background and Aims: The coronavirus disease 2019 (COVID-19) increases hyperinflammatory state, leading to acute lung damage, hyperglycemia, vascular endothelial damage, and a higher mortality rate. Metformin is a first-line treatment for type 2 diabetes and is known to have anti-inflammatory and immunosuppressive effects. Previous studies have shown that metformin use is associated with decreased risk of mortality among patients with COVID-19; however, the results are still inconclusive. This study investigated the association between metformin and the risk of mortality among diabetes patients with COVID-19. Methods: Data were collected from online databases such as PubMed, EMBASE, Scopus, and Web of Science, and reference from the most relevant articles. The search and collection of relevant articles was carried out between 1 February 2020, and 20 June 2021. Two independent reviewers extracted information from selected studies. The randomeffects model was used to estimate risk ratios (RRs), with a 95% confidence interval. Results: A total of 16 studies met all inclusion criteria. Diabetes patients given metformin had a significantly reduced risk of mortality (RR, 0.65; 95% CI: 0.54-0.80, p < 0.001, heterogeneity I 2 = 75.88, Q = 62.20, and τ 2 = 0.06, p < 0.001) compared with those who were not given metformin. Subgroup analyses showed that the beneficial effect of metformin was higher in the patients from North America (RR, 0.43; 95% CI: 0.26-0.72, p = 0.001, heterogeneity I 2 = 85.57, Q = 34.65, τ 2 = 0.31) than in patients from Europe (RR, 0.67; 95% CI: 0.47-0.94, p = 0.02, heterogeneity I 2 = 82.69, Q = 23.11, τ 2 = 0.10) and Asia (RR, 0.90; 95% CI: 0.43-1.86, p = 0.78, heterogeneity I 2 = 64.12, Q = 11.15, τ 2 = 0.40). Conclusions: This meta-analysis shows evidence that supports the theory that the use of metformin is associated with a decreased risk of mortality among diabetes patients with COVID-19. Randomized control trials with a higher number of participants are warranted to assess the effectiveness of metformin for reducing the mortality of COVID-19 patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3 390/jcm10163507/s1, Figure S1 : Searching strategy, Figure S2 : Metformin use and the risk of mortality of patients with COVID-19 (Studies included metformin users less than 1000 participants), Figure S3 : Metformin use and the risk of mortality of patients with COVID-19 (Studies included metformin users between 1000 and 10,000 participants), Figure S4 : Metformin use and the risk of mortality of patients with COVID-19 (Studies included metformin users more than 10,000 participants).
Conflicts of Interest: The authors declare no conflict of interest.
References
Abu-Jamous, Anisimovich, Baxter, Mackillop, Vizcaychipi et al., Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data, medRxiv,
doi:10.1101/2020.08.20.20174169Algire, Moiseeva, Deschênes-Simard, Amrein, Petruccelli et al., Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage, Cancer Prev. Res,
doi:10.1158/1940-6207.CAPR-11-0536Andrzejewski, Siegel, St-Pierre, Metabolic profiles associated with metformin efficacy in cancer, Front. Endocrinol,
doi:10.3389/fendo.2018.00372Ansari, Mojtahedzadeh, Kajbaf, Najafi, Khajavi et al., How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines, Adv. Ther,
doi:10.1007/s12325-008-0075-1Borges, Fujihara, Malheiros, De Ávila, Formigari et al., Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease, Am. J. Physiol. Physiol,
doi:10.1152/ajprenal.00539.2019Bramante, Buse, Tamaritz, Palacio, Cohen et al., Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity, J. Med. Virol,
doi:10.1002/jmv.26873Bramante, Ingraham, Murray, Marmor, Hovertsen et al., Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis, Lancet Health Longev,
doi:10.1016/S2666-7568(20)30033-7Cai, Ji, Treatment response between Asian and non-Asian patients with type 2 diabetes: Is there any similarity or difference?, Chin. Med. J,
doi:10.1097/CM9.0000000000000012Ceriello, De Nigris, Prattichizzo, Why is hyperglycaemia worsening COVID-19 and its prognosis?, Diabetes Obes. Metab,
doi:10.1111/dom.14098Ceriello, Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory, Diabetes Res. Clin. Pract,
doi:10.1016/j.diabres.2020.108186Chen, Liu, Ye, Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes, J. Inflamm,
doi:10.1186/s12950-016-0142-3Cheng, Liu, Li, Zhang, Lei et al., Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes, Cell Metab,
doi:10.1016/j.cmet.2020.08.013Christensen, Schiffer, Gustafsson, Krag, Nørregaard et al., Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2, Diabetes/Metab. Res. Rev,
doi:10.1002/dmrr.3091Crouse, Grimes, Li, Might, Ovalle et al., Metformin Use Is Associated with Reduced Mortality in a Diverse Population with COVID-19 and Diabetes, Front. Endocrinol,
doi:10.3389/fendo.2020.600439Desai, Roman, Rochelson, Gupta, Xue et al., Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome, Am. J. Obstet. Gynecol,
doi:10.1016/j.ajog.2013.05.001Di Xiao, Zhang, Liu, Yin, Han et al., A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients, Pharm. Pers. Med,
doi:10.2147/PGPM.S305020El-Arabey, Abdalla, Metformin and COVID-19: A novel deal of an old drug, J. Med. Virol,
doi:10.1002/jmv.25958Eskens, Zuurbier, Van Haare, Vink, Van Teeffelen, Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice, Cardiovasc. Diabetol,
doi:10.1186/1475-2840-12-175Foretz, Guigas, Viollet, Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus, Nat. Rev. Endocrinol,
doi:10.1038/s41574-019-0242-2Gao, Liu, Zhong, Liu, Zhou et al., Risk of Metformin in Patients with Type 2 Diabetes with COVID-19: A Preliminary Retrospective Report, Clin. Transl. Sci,
doi:10.1111/cts.12897Ghany, Palacio, Dawkins, Chen, Mccarter et al., Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA, Diabetes Metab. Syndr. Clin. Res. Rev,
doi:10.1016/j.dsx.2021.02.022Groen, Hamer, Snijders, Van Kranenburg, Frijns et al., Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes, J. Appl. Physiol,
doi:10.1152/japplphysiol.00919.2013Hariyanto, Kurniawan, Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obes. Med,
doi:10.1016/j.obmed.2020.100290Hashimoto, Nomura, Shoda, Isobe, Kikuchi et al., Metformin increases urinary sodium excretion by reducing phosphorylation of the sodium-chloride cotransporter, Metabolism,
doi:10.1016/j.metabol.2018.02.009Hou, Song, Li, Zhang, Wang et al., Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2010.04.017Islam, Iqbal, Walther, Atique, Dubey et al., Benzodiazepine Use and Risk of Dementia in the Elderly Population: A Systematic Review and Meta-Analysis, Neuroepidemiology,
doi:10.1159/000454881Isoda, Young, Zirlik, Macfarlane, Tsuboi et al., Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells, Arterioscler. Thromb. Vasc. Biol,
doi:10.1161/01.ATV.0000201938.78044.75Jiang, Chen, Liu, Yin, Yang et al., Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study, Diabetes Res. Clin. Pr,
doi:10.1016/j.diabres.2020.108619Jiang, Ruan, -L.; Xue, Yang, Shi et al., Metformin reduces the senescence of renal tubular epithelial cells in diabetic nephropathy via the MBNL1/miR-130a-3p/STAT3 pathway, Oxidative Med. Cell. Longev,
doi:10.1155/2020/8708236Jing, Wu, Li, Yang, Li et al., Metformin improves obesity-associated inflammation by altering macrophages polarization, Mol. Cell. Endocrinol,
doi:10.1016/j.mce.2017.09.025Jung, Lee, Lee, Kim, Metformin prevents endoplasmic reticulum stress-induced apoptosis through AMPK-PI3K-c-Jun NH2 pathway, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2011.11.073Kaneto, Kimura, Obata, Shimoda, Kaku, Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History, Int. J. Mol. Sci,
doi:10.3390/ijms22052596Khunti, Knighton, Zaccardi, Bakhai, Barron et al., Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: A nationwide observational study in England, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(21)00050-4Kow, Hasan, Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis, J. Med. Virol,
doi:10.1002/jmv.26498Kumar, Arora, Sharma, Anikhindi, Bansal et al., Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab. Syndr. Clin. Res. Rev,
doi:10.1016/j.dsx.2020.04.044Lalau, Al-Salameh, Hadjadj, Goronflot, Wiernsperger et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19, Diabetes Metab,
doi:10.1016/j.diabet.2020.101216Lally, Tsoukas, Halladay, O'neill, Gravenstein et al., Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2, J. Am. Med Dir. Assoc,
doi:10.1016/j.jamda.2020.10.031Lippi, Wong, Henry, Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): A pooled analysis, Pol. Arch. Intern. Med,
doi:10.20452/pamw.15272Lukito, Pranata, Henrina, Lim, Lawrensia et al., The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: A systematic review and meta-analysis, Diabetes Metab. Syndr. Clin. Res. Rev,
doi:10.1016/j.dsx.2020.11.006Luo, Qiu, Liu, Liu, -L.; Zheng et al., Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am. J. Trop. Med. Hyg,
doi:10.4269/ajtmh.20-0375Moher, Liberati, Tetzlaff, Altman, The et al., Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, PLoS Med,
doi:10.1371/journal.pmed.1000097Nesti, Natali, Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data, Nutr. Metab. Cardiovasc. Dis,
doi:10.1016/j.numecd.2017.04.009Oh, Song, Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: An NHIS-COVID-19 database cohort study, Acta Diabetol,
doi:10.1007/s00592-020-01666-7Ouslimani, Peynet, Bonnefont-Rousselot, Thérond, Legrand et al., Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells, Metabolism,
doi:10.1016/j.metabol.2005.01.029Poly, Islam, Yang, Lin, Jian et al., Obesity and Mortality Among Patients Diagnosed With COVID-19: A Systematic Review and Meta-Analysis, Front. Med,
doi:10.3389/fmed.2021.620044Pranata, Huang, Lim, Wahjoepramono, July, Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression, J. Stroke Cerebrovasc. Dis,
doi:10.1016/j.jstrokecerebrovasdis.2020.104949Pérez-Belmonte, Torres-Peña, López-Carmona, Ayala-Gutiérrez, Fuentes-Jiménez et al., Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: A nationwide cohort study, BMC Med,
doi:10.1186/s12916-020-01832-2Seifarth, Schehler, Schneider, Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity, Exp. Clin. Endocrinol. Diabetes,
doi:10.1055/s-0032-1327734Siri, Dastghaib, Zamani, Rahmani-Kukia, Geraylow et al., Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses, Int. J. Mol. Sci,
doi:10.3390/ijms22115992Sturmlechner, Durik, Sieben, Baker, Van Deursen, Cellular senescence in renal ageing and disease, Nat. Rev. Nephrol,
doi:10.1038/nrneph.2016.183Sukumar, Liu, Ji, Subramanian, Crompton et al., Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function, J. Clin. Investig,
doi:10.1172/JCI69589Targosz-Korecka, Malek-Zietek, Kloska, Rajfur, Stepien et al., Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier, Biochim. Biophys. Acta (BBA) Gen. Subj,
doi:10.1016/j.bbagen.2020.129533Wang, Cooper, Gokhale, Acosta-Mena, Dhalla et al., Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes, J. Clin. Endocrinol. Metab,
doi:10.1210/clinem/dgab067Wang, Van Oekelen, Mouhieddine, Del, Valle et al., A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward, J. Hematol. Oncol,
doi:10.1186/s13045-020-00934-xWu, Lee, Su, Huang, Islam et al., Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19, J. Clin. Med,
doi:10.3390/jcm10071450Xu, Liu, Xu, Xing, Ye, Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis, Clin. Exp. Pharmacol. Physiol,
doi:10.1111/1440-1681.13226Yamaoka-Tojo, Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19, Biomed. J,
doi:10.1016/j.bj.2020.08.007Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis,
doi:10.1093/cid/ciaa237Zangiabadian, Nejadghaderi, Zahmatkesh, Hajikhani, Mirsaeidi et al., The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review, Front. Endocrinol,
doi:10.3389/fendo.2021.645194Šestan, Marinović, Kavazovic, Cekinović, Wueest et al., Virus-Induced Interferon-γ Causes Insulin Resistance in Skeletal Muscle and Derails Glycemic Control in Obesity, Immunity,
doi:10.1016/j.immuni.2018.05.005
